Mallinckrodt plans expansion of commercial staff

Mallinckrodt is looking to deepen the talent pool in its commercial ops to build on its 2014 acquisitions of Questcor Pharmaceuticals and that firm's immune system drug Acthar, as well as purchase of Cadence Pharma and its Ofirmev hospital pain drug.


The Dublin-based company is naming new business managers in therapies in its autoimmune and rare-diseases segment, which was spawned by the $5.6-billion buy of Questcor last August. New leaders will also be tapped for its hospital business, Mallinckrodt said in a statement.